Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?

van de Garde, E M W; van Bedaf, L R; Hurkmans, D P; van den Heuvel, M M

doi:https://doi.org/10.1016/j.annonc.2020.09.007

Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?

DSpace/Manakin Repository

Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?

van de Garde, E M W; van Bedaf, L R; Hurkmans, D P; van den Heuvel, M M

(2020) Annals of Oncology, volume 31, issue 12, pp. 1779 - 1780

(Comment)

Download/Full Text

Open Access version via Utrecht University Repository

Publisher version

Keywords: Anti-Bacterial Agents/therapeutic use, Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms/drug therapy, Proton Pump Inhibitors, Time, Taverne

DOI: https://doi.org/10.1016/j.annonc.2020.09.007

ISSN: 0923-7534

Publisher: Oxford University Press

(Peer reviewed)

See more statistics about this item